0

Drug Evaluation: Apratastat, a Novel TACE/MMP Inhibitor for Rheumatoid Arthritis

Mohamed M Thabet, Tom W J Huizinga

Curr Opin Investig Drugs. 2006 Nov;7(11):1014-9.

PMID: 17117591

Abstract:

Wyeth Research was developing apratastat (TMI-005), one in a series of dual TNFalpha-converting enzyme and matrix metalloprotease-13 inhibitors, for the potential treatment of inflammation, especially rheumatoid arthritis. By January 2005, apratastat had entered a phase II clinical trial; however, in October 2006, Wyeth reported that it had terminated development of the drug because of lack of efficacy in this trial.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP287405510 Apratastat Apratastat 287405-51-0 Price
qrcode